首页> 美国卫生研究院文献>British Journal of Cancer >Phase I dose-escalation study to determine the safety pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

【2h】

Phase I dose-escalation study to determine the safety pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

机译：一期剂量递增研究旨在确定在先治疗失败的晚期胃肠道恶性肿瘤患者中布利伐尼丙氨酸盐联合全剂量西妥昔单抗的安全性药代动力学和药效学

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies.

机译：背景：该I期研究的目的是确定在晚期胃肠道恶性肿瘤患者中，brivani联合全剂量西妥昔单抗的安全性，药代动力学（PK），药效学和疗效。

著录项

期刊名称 British Journal of Cancer
作者
C R Garrett; L L Siu; A El-Khoueiry; J Buter; C M Rocha-Lima; J Marshall; P LoRusso; P Major; J Chemidlin; O Mokliatchouk; L Velasquez; W Hayes; D Feltquate; S Syed; S Ford; G Kollia; S Galbraith; D S A Nuyten;
展开▼
作者单位

展开▼
年(卷),期 2011(105),1
年度 2011
页码 44–52
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
antiangiogenesis brivanib cetuximab gastrointestinal tumours;

机译：抗血管生成;布里万尼;西妥昔单抗;胃肠道肿瘤;

相似文献

外文文献
中文文献

1. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy [J] . C R Garrett, L L Siu, A El-Khoueiry, British Journal of Cancer . 2011,第1期

机译：一期剂量递增研究旨在确定在先治疗失败的晚期胃肠道恶性肿瘤患者中，布利伐尼丙氨酸盐联合全剂量西妥昔单抗的安全性，药代动力学和药效学
2. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy [J] . C R Garrett, L L Siu, A El-Khoueiry, British Journal of Cancer . 2011,第1期

机译：一期剂量递增研究旨在确定在先治疗失败的晚期胃肠道恶性肿瘤患者中，布利伐尼丙氨酸盐联合全剂量西妥昔单抗的安全性，药代动力学和药效学
3. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. [J] . Jonker DJ, Rosen LS, Sawyer MB, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第6期

机译：I期研究旨在确定晚期或转移性实体瘤患者中双重VEGFR和FGFR抑制剂brivanib的安全性，药代动力学和药效学。
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. A phase I study to determine the safety pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor brivanib in patients with advanced or metastatic solid tumors [O] . D. J. Jonker, L. S. Rosen, M. B. Sawyer, -1

机译：一期研究用于确定晚期或转移性实体瘤患者中双重VEGFR和FGFR抑制剂brivanib的安全性药代动力学和药效学
6. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy [O] . Garrett, C R, Siu, L L, El-Khoueiry, A, 2011

机译：一期剂量递增研究旨在确定在先治疗失败的晚期胃肠道恶性肿瘤患者中，布利伐尼丙氨酸盐联合全剂量西妥昔单抗的安全性，药代动力学和药效学

Phase I dose-escalation study to determine the safety pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

摘要

著录项

相似文献

相关主题

期刊订阅